Gene Panel Classification for Lung Adenocarcinoma Survival Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lung cancer treatment methods lack personalized biomarkers for predicting prognosis, drug response, and adverse effects, leading to varying outcomes among patients with the same histopathologic type and stage.
Innovation Solution
A gene panel comprising molecular subtype and survival risk assessment genes, including proliferation, immune, and intercellular substance-related genes, to determine the molecular subtype and survival risk of lung adenocarcinoma, using agents like primers and probes for detecting gene expression levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional pathological typing and clinical staging are used for lung cancer treatment, then treatment standardization is achieved, but personalized prognosis prediction and treatment response assessment are insufficient
Solution Approach 1:
The patent segments lung adenocarcinoma into five distinct molecular subtypes (LAD1-LAD5) based on gene expression profiles of specific gene panels. This segmentation allows personalized treatment strategies for each subtype while maintaining the overall diagnostic framework, directly addressing the need for both standardization and personalization in lung cancer treatment
Solution Approach 2:
The patent changes the diagnostic parameters from traditional histopathologic type and clinical stage to molecular subtype classification based on gene expression levels. By measuring expression levels of specific genes (e.g., ALK, ROS1, KRAS, EGFR) and calculating subtype scores, the system achieves precise prognosis prediction and treatment response assessment that traditional methods cannot provide
2Measurement precision
If gene expression detection is performed to achieve precise molecular subtype classification, then personalized prognosis prediction is improved, but diagnostic complexity and cost increase
Solution Approach 1:
The diagnostic system is segmented into modular components: specific gene panels for different molecular subtypes (LAD1-LAD5), each with defined gene sets and calculation methods. This modularity allows laboratories to implement only the necessary detection components for their specific needs, reducing overall system complexity while maintaining classification precision
Solution Approach 2:
The patent develops universal diagnostic products (kits, reagents, detection systems) that can identify multiple molecular subtypes simultaneously using a single comprehensive gene panel. This multi-functional approach eliminates the need for separate detection systems for each subtype, reducing diagnostic complexity and cost while maintaining high classification precision
Data Source
AI summary
Disclosed is a gene panel which can evaluate lung adenocarcinoma molecular subtype and survival risk, and an application of a reagent, which detects the gene expression level of the gene panel, in preparing a product. The product is used for determining lung adenocarcinoma molecular subtype and evaluating lung adenocarcinoma patient survival risk. The product comprises a Next-Generation Sequencing (NGS) detection reagent kit, a fluorescence quantitative PCR detection reagent kit, a gene chip and a protein microarray. Also disclosed is a method which uses the detection reagent kits to evaluate lung adenocarcinoma molecular subtype and survival risk.